

# Gene therapy can correct forms of severe combined immunodeficiency

May 24 2012

---

Severe combined immunodeficiency is defect in the immune system that results in a loss of the adaptive immune cells known as B cells and T cells. Mutations in several different genes can lead to the development of severe combined immunodeficiency, including mutation of the adenosine deaminase (ADA) gene.

Traditional treatment options, such as [enzyme replacement therapy](#), are of limited efficacy, but [bone marrow transplant](#) from a compatible donor leads to a better response. A recent clinical trial indicated that gene therapy to insert the correct ADA gene in the patient's own [bone marrow cells](#) can also lead to a good response.

However, patients were noted to have defects in B cell tolerance, meaning that some [B cells](#) that react to antigens from the body fail to be eliminated, leading to an autoimmune response. Dr. Eric Meffre and colleagues at Yale University in New Haven, Connecticut and Alessandro Aiuti in Milan, Italy joined together to better understand why patients developed B cell tolerance problems. They found that loss of the ADA gene directly contributes to B cell tolerance problems and that these defects are mostly corrected after gene therapy.

Their results point to a previously unknown role for ADA in B cell response and support the use of gene therapy as an effective treatment option for ADA-deficient severe combined immunodeficiency patients.

**More information:** Defective B cell tolerance in adenosine deaminase

deficiency is corrected by gene therapy, *Journal of Clinical Investigation*.

Provided by Journal of Clinical Investigation

Citation: Gene therapy can correct forms of severe combined immunodeficiency (2012, May 24)  
retrieved 23 April 2024 from

<https://medicalxpress.com/news/2012-05-gene-therapy-severe-combined-immunodeficiency.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.